Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty stocks drag markets down
Fri, 24 Aug 11:30 am

Indian equity markets continued to trade weak over the last two hours of trade on back of heavy selling pressure witnessed across industry heavyweights. Realty and capital goods stocks witnessed maximum selling pressure.

The Sensex today is down by 51 points, while the NSE-Nifty today is down by 22 points. BSE Mid Cap index and the BSE Small Cap index are down by 0.50% and 0.37% respectively. The rupee is trading at 55.36 to the US dollar.

Energy stocks are trading in the red led by Essar Oil and Reliance Industries. According to a leading financial daily, Oil and Natural Gas Corporation Ltd. (ONGC)'s plans to move out of the coal bed methane (CBM) business and focus on the conventional oil and gas exploration and production business may face more delay. The company was forced by the Ministry of Petroleum and Natural Gas to cancel bidding for farming out CBM blocks. They would now opt for international bids. However, existing suitors may not be interested anymore. UK listed Great Eastern Energy Corporation (GEECL), Brisbane-based Dart Energy, and Essar Energy, which had earlier bid for the stake, may not participate in the re-bid. These companies are upset by the government's intervention in the matter.

Pharma stocks are trading strong led by Aurobindo Pharma and Opto Circuits. According to a leading financial daily, Pfizer Inc, the parent company of Pfizer India, has terminated its three-year old supply deal with Claris Lifesciences, immediately after a ban on the company's US sales was lifted. Pfizer lost two crucial years when the ban was in force and did not see any major business coming from generic injectables made by Claris. Claris entered into an agreement with Pfizer in 2009 to gain access to markets in North America, Europe and Australia. The deal allowed the company to sell 15 off-patent parenteral products made by Claris in the Western markets under its own brand name and add more products to its global generic basket worth US$ 10 bn. However, in 2010, the US regulator (USFDA) issued a warning to Claris over quality issues and banned the company from selling its products in the US until it complied with the issues.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty stocks drag markets down". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.